The FDA on September 26, 2023, approved BOSULIF® for pediatric patients 1 year of age and older with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. The FDA also approved a new capsule dosage form available in strengths of 50 mg and 100 mg. BOSULIF® is a product of Pfizer.
Bottom Ad
Advertisement
Subscribe
